IRVING, Texas, May 18, 2011 (GLOBE NEWSWIRE) -- Caris Life Sciences, Inc., a leading bioscience company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, this weekend presented a poster highlighting the potential of a circulating microvesicle ("cMV") -based prostate cancer test. The poster, which was presented at the American Urological Association ("AUA") 2011 Annual Meeting, demonstrated the use of a cMV assay as a potentially powerful diagnostic tool for detecting prostate cancer. Data demonstrated that the assay holds promise as a more accurate aid in the detection of prostate cancer than current testing methods.
